Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Michael_Yang
|
| gptkbp:clinicalTrialPhase |
type 1 diabetes
|
| gptkbp:collaboratedWith |
gptkb:CRISPR_Therapeutics
|
| gptkbp:developedBy |
implantable cell therapy products
stem cell-derived therapies for diabetes |
| gptkbp:focusesOn |
regenerative medicine
stem cell therapy diabetes treatment |
| gptkbp:formerName |
gptkb:Novocell
|
| gptkbp:foundedYear |
1999
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ViaCyte
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:PEC-Direct
gptkb:PEC-Encap |
| gptkbp:specializesIn |
cell replacement therapies
|
| gptkbp:website |
https://www.viacyte.com/
|
| gptkbp:bfsParent |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|